Nursing Expert Discussed Living With Neurofibromatosis Type 1

A Houston-based nursing specialist shared how patient-centered communication improves care for those with NF1.

Updated on Oct. 10, 2026 in Cancer

Gouache-painted editorial illustration featuring a stethoscope and blank note cards, representing empathetic clinical care and patient-centered communication.
Nursing specialist Victoria McClosky emphasized goal-concordant care for patients managing neurofibromatosis type 1 at the 2026 Oncology Nurse Advisor Summit. AI Illustration. Upload story photo >

Live Poll

Do you believe medical providers with personal experience of a condition offer better patient care?

At the 11th annual Oncology Nurse Advisor Summit in 2026, Victoria McClosky, a nursing development specialist at the University of Texas MD Anderson Cancer Center, detailed her clinical and personal experiences with neurofibromatosis type 1. Her presentation emphasized the importance of goal-concordant care for patients managing the genetic condition.

Why it matters

Understanding the patient perspective is vital for managing genetic disorders like NF1, where ongoing medical innovation requires both clinical expertise and empathetic communication. For Houston patients, integrating validated patient experiences into nursing care can significantly improve the quality of support during treatment.

The discussion presented at the 2026 summit drew on institutional experience from the MD Anderson Cancer Center and professional nursing standards. The efficacy of recent therapeutic advancements for NF1 remains a subject of ongoing clinical observation.

The players

Victoria McClosky

A nursing professional development specialist at the University of Texas MD Anderson Cancer Center who provides insights on living with neurofibromatosis type 1.

University of Texas MD Anderson Cancer Center

A Houston-based comprehensive cancer center that conducts clinical research and provides specialized patient care for genetic and oncological conditions.

The details

Neurofibromatosis type 1 is a complex genetic condition that can lead to the development of plexiform neurofibromas. Treatment strategies have evolved with the approval of MEK inhibitors, including selumetinib in 2020 and mirdametinib in 2025, which help manage symptomatic inoperable tumors. Beyond medication, nursing care utilizes goal-concordant communication to align clinical interventions with patient priorities, ensuring that the emotional and physical needs of individuals with NF1 are met.

Timeline

  1. 2020: The FDA approved the first MEK inhibitor for pediatric patients with symptomatic inoperable plexiform neurofibromas.

  2. Early 2025: Victoria McClosky underwent hip surgery.

  3. 2025: The FDA approved mirdametinib as the second MEK inhibitor for NF1-related plexiform neurofibromas.

  4. 2026: The 11th annual Oncology Nurse Advisor Summit was held.

Health Landscape

The care of neurofibromatosis type 1 has shifted from strictly symptom management to incorporating targeted therapies like MEK inhibitors. This evolution mirrors broader trends in personalized medicine where patient-centered communication is as critical as pharmaceutical intervention.

Patients with NF1 should discuss the role of new MEK inhibitor therapies and goal-concordant care with their healthcare team. Identifying personal sources of joy and validating one's own feelings are practical strategies worth sharing during your next clinical appointment.

The takeaway

The clinical management of neurofibromatosis type 1 is increasingly combining targeted pharmaceutical options with personalized, goal-concordant nursing care. Patients are encouraged to maintain an open dialogue with their care providers to ensure that both physical and emotional needs are prioritized.

Further reading

Learn more about the latest innovations and support resources in Cancer.

Source note: This article includes information reported by Oncology Nurse Advisor.

Live Poll

Do you believe medical providers with personal experience of a condition offer better patient care?